ATE528286T1 - 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs - Google Patents
4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebsInfo
- Publication number
- ATE528286T1 ATE528286T1 AT07869645T AT07869645T ATE528286T1 AT E528286 T1 ATE528286 T1 AT E528286T1 AT 07869645 T AT07869645 T AT 07869645T AT 07869645 T AT07869645 T AT 07869645T AT E528286 T1 ATE528286 T1 AT E528286T1
- Authority
- AT
- Austria
- Prior art keywords
- methylpyridine
- carboxamide
- hydroxymethyl
- tert
- phenyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- -1 {3-tert-Butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}-carbamoyl Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87583106P | 2006-12-20 | 2006-12-20 | |
| PCT/US2007/088371 WO2008079972A2 (en) | 2006-12-20 | 2007-12-20 | 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE528286T1 true ATE528286T1 (de) | 2011-10-15 |
Family
ID=39511117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07869645T ATE528286T1 (de) | 2006-12-20 | 2007-12-20 | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100150863A1 (de) |
| EP (1) | EP2134677B1 (de) |
| JP (1) | JP2010514692A (de) |
| AT (1) | ATE528286T1 (de) |
| CA (1) | CA2672951A1 (de) |
| ES (1) | ES2371723T3 (de) |
| WO (1) | WO2008079972A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| WO2004113274A2 (en) * | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| RS52625B (sr) | 2003-07-23 | 2013-06-28 | Bayer Healthcare Llc | Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| WO2021013712A1 (en) | 2019-07-19 | 2021-01-28 | Anagenesis Biotechnologies S.A.S. | Polyaromatic urea derivatives and their use in the treatment of muscle diseases |
| EP4029501A1 (de) | 2021-01-19 | 2022-07-20 | Anagenesis Biotechnologies | Kombination von polyaromatischen harnstoffderivaten und glucocorticoid- oder hdac-inhibitor zur behandlung von krankheiten oder störungen im zusammenhang mit muskelzellen und/oder satellitenzellen |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6040166A (en) | 1985-03-28 | 2000-03-21 | Roche Molecular Systems, Inc. | Kits for amplifying and detecting nucleic acid sequences, including a probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE3938907C2 (de) | 1989-11-24 | 1999-11-04 | Dade Behring Marburg Gmbh | Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| CA2036946C (en) | 1990-04-06 | 2001-10-16 | Kenneth V. Deugau | Indexing linkers |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| WO1992007095A1 (en) | 1990-10-15 | 1992-04-30 | Stratagene | Arbitrarily primed polymerase chain reaction method for fingerprinting genomes |
| ES2155822T3 (es) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | Compuestos y su utilizacion en una estrategia de sintesis binaria. |
| WO1993009128A1 (en) | 1991-11-07 | 1993-05-13 | Nanotronics, Inc. | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system |
| US5348853A (en) | 1991-12-16 | 1994-09-20 | Biotronics Corporation | Method for reducing non-specific priming in DNA amplification |
| US5262311A (en) | 1992-03-11 | 1993-11-16 | Dana-Farber Cancer Institute, Inc. | Methods to clone polyA mRNA |
| ATE231920T1 (de) | 1992-03-11 | 2003-02-15 | Dana Farber Cancer Inst Inc | Methode um mrna zu klonieren |
| EP0672187A4 (de) | 1992-10-08 | 1999-11-17 | Univ California | Pcr-testverfahren zur bestimmung der anwesenheit und konzentration einer zielsubstanz. |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| EP0706649B1 (de) | 1994-04-29 | 2001-01-03 | Perkin-Elmer Corporation | Verfahren und vorrichtung zur echtzeiterfassung der produkte von nukleinsäureamplifikation |
| US5707624A (en) | 1994-06-03 | 1998-01-13 | The Regents Of The University Of Michigan | Treatment of Kaposi's sarcoma by inhibition of scatter factor |
| US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US5723290A (en) | 1994-11-03 | 1998-03-03 | Trustees Of The University Of Pennsylvania | Methods for profiling mRNA expression in neurites |
| ATE397097T1 (de) | 1995-03-17 | 2008-06-15 | Wayne John Cancer Inst | Nachweis von brustmetastasen unter verwendung eines mehrfachmarker-tests |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US5646036A (en) | 1995-06-02 | 1997-07-08 | Genentech, Inc. | Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies |
| US6214344B1 (en) | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| US5994063A (en) | 1995-06-23 | 1999-11-30 | Metzker; Michael L. | Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for homogenous amplification/detection assays |
| US5712126A (en) | 1995-08-01 | 1998-01-27 | Yale University | Analysis of gene expression by display of 3-end restriction fragments of CDNA |
| WO1997018454A2 (en) | 1995-11-16 | 1997-05-22 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| EP0914830B1 (de) | 1996-03-25 | 2003-11-19 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält |
| JP2000515735A (ja) | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6723694B1 (en) | 1997-05-21 | 2004-04-20 | The Children's Medical Center Corp. | Short peptides which selectively modulate intracellular signalling |
| US6051593A (en) | 1997-06-20 | 2000-04-18 | Sugen, Inc. | 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors |
| EP1028953A1 (de) | 1997-11-03 | 2000-08-23 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatische heterocyclische verbindungen als antiinflammatorische mittel |
| DE19754482A1 (de) | 1997-11-27 | 1999-07-01 | Epigenomics Gmbh | Verfahren zur Herstellung komplexer DNA-Methylierungs-Fingerabdrücke |
| ES2154253T3 (es) | 1997-12-22 | 2012-01-27 | Bayer Healthcare Llc | Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas. |
| EP1449834A3 (de) | 1997-12-22 | 2004-12-22 | Bayer Corporation | Hemmung der RAF-Kinase unter Verwendung von symmetrisch und unsymmetrisch substituierten Harnstoffen |
| DE69834842T2 (de) | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen |
| DE69836563T2 (de) | 1997-12-22 | 2007-05-16 | Bayer Pharmaceuticals Corp., West Haven | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN |
| EP1047418B1 (de) | 1997-12-22 | 2005-07-27 | Bayer Pharmaceuticals Corp. | Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen |
| IL136737A0 (en) | 1997-12-22 | 2001-06-14 | Bayer Ag | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| EP1140840B1 (de) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US6297238B1 (en) | 1999-04-06 | 2001-10-02 | Basf Aktiengesellschaft | Therapeutic agents |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| IL148718A0 (en) | 1999-09-17 | 2002-09-12 | Abbott Gmbh & Co Kg | Pyrazolopyrimidines as therapeutic agents |
| CA2443950C (en) | 2001-04-20 | 2011-10-18 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US6589997B2 (en) | 2001-06-29 | 2003-07-08 | North Shore-Long Island Jewish Health System | Small-molecule modulators of hepatocyte growth factor/scatter factor activities |
| US20030207872A1 (en) * | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US6790852B2 (en) | 2002-04-18 | 2004-09-14 | Hoffmann-La Roche Inc. | 2-(2,6-dichlorophenyl)-diarylimidazoles |
| US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| MXPA05009104A (es) | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Derivados de urea biciclica novedosa utiles en el tratamiento del cancer y otros trastornos. |
| ATE517885T1 (de) * | 2004-04-30 | 2011-08-15 | Bayer Healthcare Llc | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
| DE102005015253A1 (de) * | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
-
2007
- 2007-12-20 US US12/520,618 patent/US20100150863A1/en not_active Abandoned
- 2007-12-20 AT AT07869645T patent/ATE528286T1/de not_active IP Right Cessation
- 2007-12-20 CA CA002672951A patent/CA2672951A1/en not_active Abandoned
- 2007-12-20 ES ES07869645T patent/ES2371723T3/es active Active
- 2007-12-20 WO PCT/US2007/088371 patent/WO2008079972A2/en not_active Ceased
- 2007-12-20 EP EP07869645A patent/EP2134677B1/de not_active Not-in-force
- 2007-12-20 JP JP2009543222A patent/JP2010514692A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2134677B1 (de) | 2011-10-12 |
| WO2008079972A3 (en) | 2008-08-14 |
| US20100150863A1 (en) | 2010-06-17 |
| JP2010514692A (ja) | 2010-05-06 |
| WO2008079972A2 (en) | 2008-07-03 |
| CA2672951A1 (en) | 2008-07-03 |
| ES2371723T3 (es) | 2012-01-09 |
| EP2134677A2 (de) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE498620T1 (de) | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)-pheny ü-1h-pyrazol-5-ylü-carbamoyl)-aminoü-3- fluorophenoxyü -n-methylpyridin-2-carboxamid sowie prodrugs und salze davon zur behandlung von krebs | |
| ATE528286T1 (de) | 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs | |
| CY1117287T1 (el) | Πυρρολιδινονη ως αναστολεις metap-2 | |
| DK1934174T3 (da) | Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme | |
| EA201100880A1 (ru) | Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина | |
| ATE522509T1 (de) | Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase | |
| EA200800182A1 (ru) | Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3 | |
| CY1112117T1 (el) | Υδροξυλιωμενες και μεθοξυλιωμενες κυκλοπεντα[d]πυριμιδινες ως αναστολεις ακτ πρωτεϊνικης κινασης | |
| ATE554087T1 (de) | Neue kinaseinhibitoren | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| CY1113443T1 (el) | Παραγωγα πυριδαζινονης | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
| DK1836201T3 (da) | Pyrrolidininhibitorer af IAP | |
| EA201100992A1 (ru) | Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы | |
| EA200970605A1 (ru) | Ингибиторы mapk/erk-киназ | |
| EA201100035A1 (ru) | Производные тиазолилпиперидина | |
| ATE532789T1 (de) | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren | |
| EA200901601A1 (ru) | Производные пиридазинона | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| GEP20125712B (en) | Method for preparation of piperazine compounds and hydrochloride salts thereof | |
| EA201000550A1 (ru) | Производные тиазола | |
| CY1114865T1 (el) | Νεοι αναστολεις seh και η χρηση toyς | |
| CR20120171A (es) | Uso de n-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi) fenil)-4-(4-metil-2-tienil)-1-ftalazinamina en el tratamiento de cáncer resistente al agente antimitótico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |